Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Lung
Descriptor: HGF/SF expression


Reference Number: 88
Eagles, G. et al. Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Br J Cancer 73, 377-81 (1996).
PubMed link      E-mail link

Reference Number: 89
Harvey, P. et al. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 180, 389-94 (1996).
PubMed link      E-mail link

Reference Number: 90
Olivero, M. et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 74, 1862-8 (1996).
PubMed link      E-mail link

Reference Number: 91
Tsao, M. S., Yang, Y., Marcus, A., Liu, N. & Mou, L. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum Pathol 32, 57-65. (2001).
PubMed link      E-mail link

Reference Number: 246
Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C, Antoine M, Soler P, Cadranel J. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res 63:1405-12 (2003).
PubMed link      E-mail link

Reference Number: 247
Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM, Flavia Di Renzo M. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 288:382-9 (2003).
PubMed link      E-mail link

Reference Number: 319
Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, Salgia R. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 24, 1031-8 (2004
PubMed link      E-mail link

Reference Number: 320
Masuya D, Huang C, Liu D, Nakashima T, Kameyama K, Haba R, Ueno M, Yokomise H. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 90, 1555-62 (2004)
PubMed link      E-mail link

Reference Number: 369
Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem. 281, 13005-8 (2006)
PubMed link      E-mail link

Reference Number: 387
Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis. Mar 2; [Epub ahead of print] (2006)
PubMed link      E-mail link

Reference Number: 394
Hakuma N, Kinoshita I, Shimizu Y, Yamazaki K, Yoshida K, Nishimura M, Dosaka-Akita H. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells. Cancer Res. 65, 10776-82 (2005)
PubMed link      E-mail link

Reference Number: 395
Sugimoto T, Takiguchi Y, Kurosu K, Kasahara Y, Tanabe N, Tatsumi K, Hiroshima K, Minamihisamatsu M, Miyamoto T, Kuriyama T. Growth factor-mediated interaction between tumor cells and stromal fibroblasts in an experimental model of human small-cell lung cancer. Oncol Rep. 14, 823-30 (2005)
PubMed link      E-mail link

Reference Number: 438
Chen JT, Lin TS, Chow KC, Huang HH, Chiou SH, Chiang SF, Chen HC, Chuang TL, Lin TY, Chen CY. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol. 34, 264-73 (2006)
PubMed link      E-mail link

Reference Number: 570
Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, Fukayama M. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 98, 1006-13 (2007)
PubMed link      E-mail link

Reference Number: 601
Chen JT, Huang CY, Chiang YY, Chen WH, Chiou SH, Chen CY, Chow KC. HGF Increases Cisplatin Resistance via Down-Regulation of AIF in Lung Cancer Cells. Am J Respir Cell Mol Biol. 38, 559-65 (2008)
PubMed link      E-mail link

Reference Number: 602
Pierce A, Barron N, Linehan R, Ryan E, O'Driscoll L, Daly C, Clynes M. Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. Eur J Cancer. 44, 151-9 (2008)
PubMed link      E-mail link

Reference Number: 692
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479-87 (2008)
PubMed link      E-mail link

Reference Number: 798
Wang X, Li K, Chen H, Wang D, Zhang Y, Bai C. Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med. 14, 833-9 (2010)
PubMed link      E-mail link

Reference Number: 932
Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther. 9, 2785-92 (2010)
PubMed link      E-mail link

Reference Number: 937
Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL. Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-ß enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193, 114-32 (2011)
PubMed link      E-mail link

Reference Number: 944
Korobko IV, Zinov'eva MV, Allakhverdiev AK, Zborovskaia IB, Svwrdlov ED. [c-Met and HGF expression in non-small-cell lung carcinomas]. Mol Gen Mikrobiol Virusol. 18-21 (2007)
PubMed link      E-mail link

Reference Number: 945
Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther. 5, 2388-97 (2006)
PubMed link      E-mail link

Reference Number: 1070
Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, Salgia R. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 30, 341-54 (2011)
PubMed link      E-mail link

Reference Number: 1074
Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res. 17, 2260-9 (2011)
PubMed link      E-mail link

Reference Number: 1075
Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K. Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. Int J Cancer. 129, 1410-6 (2011)
PubMed link      E-mail link

Reference Number: 1077
Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K, Yasumoto K. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol. 5, 591-6 (2010)
PubMed link      E-mail link

Reference Number: 1079
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17, 77-88 (2010)
PubMed link      E-mail link

Reference Number: 1080
Yamamoto BJ, Elias PD, Masino JA, Hudson BD, McCoy AT, Anderson ZJ, Varnum MD, Sardinia MF, Wright JW, Harding JW. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther. 333, 161-73 (2010)
PubMed link      E-mail link

Reference Number: 1081
Navab R, Liu J, Seiden-Long I, Shih W, Li M, Bandarchi B, Chen Y, Lau D, Zu YF, Cescon D, Zhu CQ, Organ S, Ibrahimov E, Ohanessian D, Tsao MS. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia. 11, 1292-300 (2009)
PubMed link      E-mail link

Reference Number: 1082
Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res. 16, 174-83
PubMed link      E-mail link

Reference Number: 1083
Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 15, 6630-8 (2009)
PubMed link      E-mail link

Reference Number: 1085
Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69, 8009-16 (2009)
PubMed link      E-mail link

Reference Number: 1089
Kishi Y, Kuba K, Nakamura T, Wen J, Suzuki Y, Mizuno S, Nukiwa T, Matsumoto K, Nakamura T. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci. 100, 1351-8 (2009)
PubMed link      E-mail link

Reference Number: 1090
. Epub 2009 May 12. Kishi Y, Kuba K, Nakamura T, Wen J, Suzuki Y, Mizuno S, Nukiwa T, Matsumoto K, Nakamura T. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci. 100, 1351-8 (2009)
PubMed link      E-mail link

Reference Number: 1092
Kubota T, Taiyoh H, Matsumura A, Murayama Y, Ichikawa D, Okamoto K, Fujiwara H, Ikoma H, Nakanishi M, Kikuchi S, Sakakura C, Ochiai T, Kokuba Y, Taniguchi H, Sonoyama T, Matsumoto K, Nakamura T, Otsuji E. NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin Exp Metastasis. 26, 447-56 (2009)
PubMed link      E-mail link

Reference Number: 1093
Chiang YY. Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells. Mol Carcinog. 48, 662-70 (2009)
PubMed link      E-mail link

Reference Number: 1104
Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer. 74, 293-9 (2011)
PubMed link      E-mail link

Reference Number: 1151
Hosoda H, Izumi H, Tukada Y, Takagiwa J, Chiaki T, Yano M, Arai H. Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients. Ann Thorac Cardiovasc Surg. 18, 1-7 (2012)
PubMed link      E-mail link

Reference Number: 1168
Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, Sato Y, Goya T, Noguchi M. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. Lung Cancer. 75, 181-8 (2012)
PubMed link      E-mail link

Reference Number: 1170
Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 6, 2011-7 (2011)
PubMed link      E-mail link

Reference Number: 1216
Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 7, 1078-85 (2012)
PubMed link      E-mail link

Reference Number: 1217
Ujiie H, Tomida M, Akiyama H, Nakajima Y, Okada D, Yoshino N, Takiguchi Y, Tanzawa H. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res. 32, 3251-8 (2012)
PubMed link      E-mail link

Reference Number: 1220
Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Anticancer Res. 32, 3785-90 (2012)
PubMed link      E-mail link

Reference Number: 1229
Liu Y, Yang Y, Ye YC, Shi QF, Chai K, Tashiro S, Onodera S, Ikejima T. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. J Pharmacol Sci. 118, 423-32 (2012)
PubMed link      E-mail link

Reference Number: 1291
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 11, 2149-57 (2012)
PubMed link      E-mail link

Reference Number: 1366
Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8, e62104 (2013)
PubMed link      E-mail link

Reference Number: 1402
Casaluce F1, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol. 8, 55-67 (2013)
PubMed link      E-mail link

Reference Number: 1437
Ramanujum R1, Lin YL, Liu JK, He S. Regulatory expression of MMP-8/MMP-9 and inhibition of proliferation, migration and invasion in human lung cancer A549 cells in the presence of HGF variants. Kaohsiung J Med Sci. 29, 530-9 (2013)
PubMed link      E-mail link

Reference Number: 1495
Telega A, Kos-Kudla B, Foltyn W, Blicharz-Dorniak J, Rosiek V. Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoids. Endokrynol Pol. 63, 477-82 (2012)
PubMed link      E-mail link

Reference Number: 1506
Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8, e62104 (2013)
PubMed link      E-mail link

Reference Number: 1514
Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB, Walgren RA. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Clin Cancer Res. 19, 5699-710 (2013)
PubMed link      E-mail link

Reference Number: 1515
Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anticancer Drugs. 24, 1039-46 (2013)
PubMed link      E-mail link

Reference Number: 1553
Johnson H, Lescarbeau RS, Gutierrez JA, White FM. Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion. J Proteome Res. 12, 1856-67 (2013)
PubMed link      E-mail link

Reference Number: 1636
Fang MY, Wang SY, Zheng YB, Gong LY, Bao WL, Gu DL, Mao WM. Prognostic and predictive significance of plasma hepatocyte growth factor and carcinoembryonic antigen in non-small lung cancer after surgery. Eur Rev Med Pharmacol Sci. 18, 398-403 (2014)
PubMed link      E-mail link

Reference Number: 1670
Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer. 86, 195-200 (2014)
PubMed link      E-mail link

Reference Number: 1708
Cañadas I, Taus A, González I, Villanueva X, Gimeno J, Pijuan L, Dómine M, Sánchez-Font A, Vollmer I, Menéndez S, Arpí O, Mojal S, Rojo F, Rovira A, Albanell J, Arriola E High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget. 5, 5246-56 (2014)
PubMed link      E-mail link

Reference Number: 1722
Zhang N, Xie F, Gao W, Yu S, Qiu L, Lin W, Sun Y, Jia T Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis. Mol Med Rep. 11, 2797-804 (2015)
PubMed link      E-mail link

Reference Number: 1725
Umeguchi H, Sueoka-Aragane N, Kobayashi N, Nakamura T, Sato A, Takeda Y, Hayashi S, Sueoka E, Kimura S Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Oncol Rep. 33, 391-6 (2015)
PubMed link      E-mail link

Reference Number: 1777
Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Mol Cancer Ther. 14, 533-41 (2015)
PubMed link      E-mail link

Reference Number: 1779
Wu H, Fan F, Liu Z, Shen C, Wang A, Lu Y. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway. Cancer Chemother Pharmacol. 76, 307-15 (2015)
PubMed link      E-mail link

Reference Number: 1885
Yu H, Wang Y, Yu Q, Zhang H, Ma W, Shang S, Wang D Significance of plasma hepatocyte growth factor in diagnosis of benign and malignant solitary pulmonary nodules. Int J Clin Exp Pathol. 8, 2063-7 (2015)
PubMed link      E-mail link